2026-08125Notice

FDA Extends Pain Drug Advisory Panel for Two Years

Published Date: 4/27/2026

Notice

Summary

The FDA is renewing its Anesthetic and Analgesic Drug Products Advisory Committee for two more years, keeping it active until May 1, 2028. This committee helps make sure pain and anesthesia drugs are safe and effective, especially focusing on issues like opioid abuse. The renewal means the committee will keep advising the FDA without any new costs or delays.

No Economic Impacts Identified for this Document

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
4/27/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register